ProCE Banner Activity

MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM

Slideset Download
Conference Coverage
After 4 years of follow-up, addition of daratumumab to lenalidomide/dexamethasone reduced the risk of progression or death by 46% and tripled the rate of MRD negativity.

Released: December 17, 2020

Expiration: December 16, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology